Navigation Links
LSUHSC awarded $2 million dollar grant to prevent pneumonia linked to immune deficiency
Date:7/13/2010

New Orleans, LA Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia (PCP), which can be a complication of HIV/AIDS. It can also be a complication of cancer, organ or bone marrow transplantation, as well as the chronic use of corticosteroids or other medications that affect the immune system.

Pneumocystis carinii pneumonia remains an important clinical problem and although there is a well-known relationship between CD4 cell count and the risk of Pneumocystis carinii infection, defense mechanisms against it are not fully understood. Dr. Kolls and his research team will study the role of a subset of CD4 cells which he believes are missing in Pneumocystis carinii infection and which when restored, produce an effective immune response to the infection. These are the T-helper cells, Th1, Th2, and Th17. The research funded under this grant will determine the role of interleukin-23 and interleukin-12 in regulating Th1 immunity to Pneumocystis carinii, and the team hopes to show that by vaccinating genetically engineered mice with CD4+ T-cells belonging to any of these T-cell subsets, immunity will be sufficient to protect against PCP.

"This research will define the types of T-cells that are needed to prevent this life-threatening infection," notes Dr. Kolls. "It is our hope that vaccines can activate these cells to prevent or treat PCP."

According to the Centers for Disease Control and Prevention, Pneumocystis pneumonia (PCP), which is caused by Pneumocystis jirovecii (formerly P. carinii), is frequently the first serious illness encountered by HIV-infected persons. During the early years of the AIDS epidemic, PCP was the AIDS-defining illness for as many as two thirds of patients in the United States. Although a decline in incidence of PCP occurred during the era of highly active antiretroviral therapy (HAART), PCP remains the most common serious opportunistic illness in HIV-infected persons. Patients in the developing world without access to PCP prophylaxis or antiretroviral drugs remain at high risk, and PCP continues to develop in certain groups in industrialized countries. There is also a potential for drug resistance to develop.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC awarded patent for compound inhibiting cancer and other diseases
2. LSUHSC research identifies key contributor to Alzheimers disease process
3. LSUHSC student awarded top national honor for diabetes research
4. LSUHSC public health researcher finds reason for weight gain
5. LSUHSC research describes function of key protein in cancer spread
6. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
7. LSUHSC research helps link schizophrenia to specific DNA region
8. LSUHSCs Bazan awarded ARRA grant to preserve vision
9. LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
10. Grant supports LSUHSC research on how like cell receptor systems determine very different functions
11. LSUHSC researchers working to prevent diabetic neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2016)... 2016 http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ... the  "India Biometrics Authentication & Identification ...  report to their offering.  ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
(Date:1/8/2016)... 8, 2016 NXTD ), a ... ® , a privately held leading direct seller of ... 5000 fastest-growing company announced that on December 31, ... million in Nxt-ID to develop a proprietary new wireless ... ® , a unique smart wallet that serves to ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... - New FDA action date of July ... of July 22, 2016   --> ... 2016   - Lifitegrast has the potential to ... treatment of signs and symptoms of dry eye disease in adults ... the only product approved in the U.S. in the past decade indicated for the treatment ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology: